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Abstract: Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the 
gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective 
treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, 
since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Muta-
tions in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase 
receptor, an important factor in the pathogenesis of the disease. The development of speciﬁ c 
tyrosine kinase inhibitors, such as imatinib mesylate, has led to a breakthrough in the treatment 
of advanced GIST. Treatment with this drug has led to signiﬁ cant improvements in survival, with 
overall response rates in excess of 80%. Side effects are common, but usually manageable. The 
success of this drug has led to further trials investigating its use in the pre- and postoperative 
situation. This review summarizes the current knowledge of GIST and imatinib treatment and 
possible future developments.
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Introduction
Gastrointestinal stromal tumor (GIST) is a rare tumor, accounting for less than 1% of 
primary gastrointestinal (GI) neoplasms. It is, however, the commonest non-epithelial 
tumor of the gastrointestinal tract. The median age of diagnosis is approximately 60 
years, with the annual incidence estimated at 10–20 cases per million (Nilsson et al 
2005). It is very rare in children and affects males and females equally. GIST is mainly 
a disease of the GI tract, mesentery, and omentum. Most commonly, it originates 
in the stomach (60%), followed by the small intestine (30%), the colon and rectum 
(5%), and the oesophagus (5%) (Van der Zwan and DeMatteo 2005). Many are found 
incidentally at surgery or autopsy. GIST can be classiﬁ ed into different risk groups. 
At presentation, only 44% are overtly malignant or high risk, while 32% are of low 
or very low risk (Nilsson et al 2005). Although the exact pathogenesis is not fully 
known, it is thought to originate from the same lineage as the interstitial cells of Cajal. 
These are pacemaker cells of the GI tract, which are phenotypically similar to GIST 
cells (Kindblom et al 1998).
Most GISTs are spindle cell tumors, which were previously classed as either 
leiomyoma or leiomyosarcoma. Following the introduction of immunohistochemistry 
in the 1980s, Mazur and Clark coined the term GIST (Mazur and Clark 1983), but it 
was not until the 1990s that this entity was widely recognized. Most of these stromal 
tumors stained positively for CD34 (Miettinen et al 1995). In 1998, it was discovered 
that these tumors had gain of function mutations in the KIT proto-oncogene (Hirota 
et al 1998). The KIT protein is a transmembrane receptor for stem cell factor. The 
intracytoplasmic portion of this receptor functions as a tyrosine kinase. The availability 
of the immunohistochemical marker, CD117, to the KIT protein, has revolutionized 
the diagnosis of GIST, by identifying a treatment target. Approximately 95% of GISTs 
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stain positive for CD117, making it a very useful marker 
for diagnosis (Miettinen and Lasota 2001). This has led to 
the development of the targeted therapy imatinib mesylate 
(STI-571; Glivec®, Novartis, Basel, Switzerland). This drug 
inhibits several tyrosine kinase receptors with varying afﬁ n-
ity, including KIT, the BCR-ABL fusion protein, and the 
platelet derived growth factor receptor (PDGFR) (Heinrich 
et al 2000, De Giorgi and Verweij 2005).
Presentation
Because GIST was only recently recognized as a separate 
clinicopathological entity, the literature prior to 2000 did not 
give an accurate account of the clinical behavior of GIST.
GIST can present in many ways. Thirty percent are 
diagnosed incidentally on a pathological or autopsy resec-
tion specimen (Nilsson et al 2005). Small tumors may be 
asymptomatic and GISTs can grow to a large size before 
producing any symptoms. This may be because GISTs grow 
by displacing adjacent structures rather than invading them. 
Presenting symptoms can therefore include non-speciﬁ c GI 
symptoms such as nausea, vomiting, dyspepsia, abdominal 
pain, distension, or change in bowel behavior. Less com-
monly, there may be symptoms of obstruction, bleeding, or 
rupture into the peritoneal cavity.
Despite radical resection with clear margins, 40%–80% 
recur within the abdominal cavity. However, the majority 
of recurrences are solitary and thus may be resectable. The 
most common sites of metastases are the peritoneum and 
liver, whereas lymph node metastases are relatively rare. In 
contrast to leiomyosarcomas, pulmonary and bone metastases 
occur late and are uncommon.
Rare familial cases of GIST with a mutated KIT have 
been recognized. This may be as part of the Carney triad of 
gastric GIST, functioning extra-adrenal paraganglioma and 
pulmonary chondroma. This mainly affects young women 
and was ﬁ rst described in by Carney in 1977 (Carney et al 
1977). Although it is thought to be hereditary (young age and 
multiple speciﬁ c tumors), no genetic abnormality has been 
identiﬁ ed. GIST has also been reported in association with 
neuroﬁ bromatosis type 1 (Von Reckinghausen’s disease) 
(Ishida et al 1996).
GIST can range in size from less than 1 cm to over 30 
cm in diameter. Various investigations may be used in the 
diagnosis of GIST. Gastric tumors are often detected by 
endoscopy. Macroscopically, primary GIST is usually a 
well-circumscribed submucosal vascular tumor, protrud-
ing into the lumen. Computed tomography (CT) is useful 
to assess the extent of the primary disease and to assess 
for the presence of metastatic disease. Magnetic resonance 
imaging (MRI) may provide further soft tissue delineation. 
Positron emission tomography (PET) with the tracer 18-
ﬂ uorodeoxyglucose (18-FDG) demonstrates intense uptake, 
but may not distinguish GIST from other malignancies. 
Its main use is in demonstrating the presence or absence 
of metastases.
Smaller tumors are usually treated by excision biopsy. For 
larger lesions, the use of preoperative biopsy is controversial. 
This is because there is a risk of tumor rupture, hemorrhage, 
and perforation of viscera (Joensuu et al 2002). The diagnos-
tic yield from endoscopic biopsy is approximately 50%.
Diagnosis
Macroscopically, GIST has the appearance of a friable unen-
capsulated mass arising from the muscle layer, rather than 
the epithelium. Central necrosis is often present in larger 
lesions (D’Amato et al 2005). Microsopically, most GISTs 
consist of a uniform population of spindle cells (70%). Some 
are characterized as epithelioid type (20%), which typically 
arise in the stomach (Miettinen et al 2002). The remaining 
10% consist of a mixture of these two morphologies. The 
spindle cells are arranged in short fasicles or whorls, with 
prominent nuclear palisading. Either type may contain cur-
vilinear collections of extracellular collagen called skeinoid 
ﬁ bres (Corless et al 2004). The eosinophilic subtype consists 
of rounded cells with eosinophilic or clear cytoplasm (Van 
der Zwan and DeMatteo 2005).
Ninety-ﬁ ve percent of GISTs stain positively for the 
CD117 antigen, which is an epitope for the KIT receptor tyro-
sine kinase. KIT is usually widespread and gives cytoplasmic 
staining and can show a characteristic dot-like “golgi” pattern 
(Fletcher et al 2002). Other markers which may be positive 
include BCL-2 (80%), CD34 (70%), muscle speciﬁ c actin 
(50%), smooth muscle actin (35%), s-100 (10%), and desmin 
(5%) (Corless et al 2004). KIT positivity is important as it 
is one of the targets of the tyrosine kinase inhibitor imatinib 
mesylate. KIT overexpression is common in a variety of 
tumor types including GISTs, seminomas, adenoid cystic 
carcinomas, malignant melanomas, and lung carcinomas 
(non-small cell and small cell types) (Takahashi et al 1995; 
Went et al 2004). But it is worth noting that positive staining 
for KIT does not necessarily indicate KIT activation or KIT 
mutation (Joensuu et al 2002). KIT mutations, however, are 
present in 95% of GISTs. Other research has shown activat-
ing KIT muations in seminomas, chronic myeloproliferative 
disorder, acute leukemia, mast cell neoplasia, and sinonasal 
NK/T-cell lymphoma (Miettinen et al 2002). Platelet-derived 
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growth factor receptor alpha (PDGFRα) mutations are found 
in 5%–10% GISTs (Sihto et al 2005).
Many efforts have been made to produce a reliable prog-
nostic classiﬁ cation (Table 1) (Fletcher et al 2002). Mitotic 
count and tumor size have been shown to be very important. 
A large study examined 1765 tumors for prognostic markers 
(Miettinen et al 2005). Tumours less than 10 cm with less 
than 5 mitoses per 50 high powered ﬁ elds (HPFs) had only 
a 2%–3% risk of metastases. Conversely, the metastatic rate 
for tumors greater than 10 cm, with greater than 5 mitoses 
per 50 HPFs, was as high as 86%. Non-gastric primary tumor 
location and male gender may also be independent adverse 
prognostic factors (Rutkowski et al 2007).
Evidence is now emerging that mutational analysis can 
help to predict prognosis. A recent study showed improved 
survival in those with KIT exon 11 point mutation compared 
to deletions in gastric GISTs. The same was true with com-
parison with point mutations from other locations (Steigen 
et al 2007). This is discussed further below.
Pathogenesis
GIST cells are phenotypically very similar to the KIT positive 
interstitial cells of Cajal of the GI tract. They are pacemaker 
cells which regulate motility and their development depends 
on cellular signalling regulated by the KIT protein (Miet-
tinen et al 2002). The KIT proto-oncogene on chromosome 
4 (4q11–q12) encodes for the KIT protein, which is also 
expressed on mast cells, germ cells, and hemopoietic cells. 
Stem cell factor is the ligand for this receptor and binding 
activates cell growth, differentiation, and survival. In GIST, 
ligand independent activation occurs due to the presence of 
an activating mutation, which was ﬁ rst described by Hirota 
and colleagues. They showed that GIST cells were able to 
grow without their ligand in vitro and in nude mice (Hirota 
et al 1998). Since then, many more gain-of-function muta-
tions have been identiﬁ ed (Sanborn and Blanke 2005). It 
has been shown that the site of mutation has a prognostic 
importance. The most frequent are exon 11 (65%–70%), 9 
(10%–20%), 13 (1%–2%) and 17 (1%) (Figure 1). Muta-
tions of the juxtamembrane domain (exon 11) of the KIT 
receptor are the most frequently seen, where small in-frame 
deletions and insertions or point mutations are responsible for 
ligand-independent receptor dimerization. These mutations 
are most commonly found in GIST of the stomach. Dele-
tions and insertions tend to affect the ﬁ rst part of the exon 
(especially codons 557 to 559), whereas point muations are 
limited to just 4 codons (557, 559, 560, and 576) (Corless 
et al 2004). Exon 9 mutations are located in the extracellular 
domain of the KIT receptor, whereas exons 13 and 17 encode 
for the intracellular part of the receptor (kinase 1 domain and 
activation loop respectively).
Some studies have suggested a more aggressive clinical 
behaviour in tumors with exon 11 mutations (Ernst et al 1998; 
Lasota et al 1999; Taniguchi et al 1999; Li et al 2000). Others 
have suggested that KIT mutations were not identiﬁ ed more 
commonly in higher grade GISTs (Rubin et al 2001) and that 
mutations of exon 11 were common in histologically benign 
GISTs. So there is continuing controversy as to whether 
exon 11 mutations confer aggressive behavior or not. As 
imatinib targets the ATP (adenosine triphosphate) binding 
site of the KIT receptor (encoded by exon 11), tumors with 
exon 11 mutations treated with imatinib have a signiﬁ cantly 
better partial response rate, event free and overall survival 
compared to exon 9 or no detectable mutation. A partial 
response rate of up to 83% has been achieved, showing how 
sensitive these tumors can be (Heinrich et al 2003a; Corless 
et al 2004; Debiec-Rychter et al 2006).
Not all GISTs demonstrate KIT mutation. An important 
study of 40 KIT-negative GISTs demonstrated PDGFRα 
activating mutations in 14 (35%) (Heinrich et al 2003b). 
The authors also showed that the mechanisms of cytogenetic 
progression and signal transduction were similar to those 
seen in KIT positive GISTs. These two mutational events 
are mutually exclusive of each other. Other studies have 
conﬁ rmed similar ﬁ ndings (Hirota et al 2003; Wardelmann 
et al 2004). Activating mutations of PDGFRα do not appear 
in other tumor types (Burger et al 2005; Sihto et al 2005).
KIT or PDGFRα mutations occur early in the pathogenesis 
of GIST, as they are found even in very small tumors. Progres-
sion of GIST has been shown to be related to various chromo-
somal aberrations (Gunawan et al 2002). The most common 
chromosomal aberration seen in malignant GIST are losses 
of 14q32 and 22q11.The loss of the long arm of chromosome 
Table 1 Proposed approach for defi ning risk of aggressive 
behavior in GISTs
 Size Mitotic count
Very low risk 2 cm 5/50 HPF
Low risk 2–5 cm 5/50 HPF
Intermediate risk 5 cm 6–10/50 HPF
 5–10 cm 5/50 HPF
High risk 5 cm 5/50 HPF
 10 cm Any mitotic rate
 Any size 10/50 HPF
Reproduced with permission from Fletcher CD, Berman JJ, Corless C, et al. 2002. 
Diagnosis of gastrointestinal stromal tumors:  A consensus approach. Hum Pathol, 
33:459–65. Copyright© 2002 Elsevier.
Abbreviation: HPF, high powered fi eld.
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22 is particularly associated with progression to a borderline 
or malignant lesion (Debiec-Rychter et al 2001).
Surgery
Surgery remains the standard initial management for all 
localized GISTs. The tumor should be removed en bloc, 
with a clear margin. The pseudocapsule should be removed 
and not penetrated. Therefore, a wedge resection (stomach) 
or segmental resection (intestine) is required. If neighboring 
structures are involved, en-bloc resection should still be con-
templated. Studies have evaluated the outcomes of surgery, 
comparing complete versus incomplete resections. In a series 
of 200 GISTs, median survival was 66 months for complete 
resection compared with 22 months for incomplete resection 
or unresectable disease (DeMatteo et al 2000). The complete 
resection rate was approximately 85%. The optimum surgical 
margin has not been clariﬁ ed. Lymph node dissection or 
biopsy is not recommended mainly due the pattern of spread 
of GISTs: lymph node metastases are rare.
More recently, there has been a move to laparoscopic 
surgery, particularly for gastric GISTs. One series of 50 
consecutive patients showed this approach was associated 
with low morbidity and short hospitalization. All resections 
had clear margins and the long term disease free survival was 
92% (Novitsky et al 2006). In a second series of 22 clinically 
suspected GISTs, similar ﬁ ndings were shown, with only one 
case of recurrence (Berindoague et al 2006).
Spontaneous tumor rupture, or rupture during surgery, 
increases the risk of peritoneal recurrence and is an adverse 
prognostic factor. Overall 5-year survival rates for primary 
resected disease are in the order of 50%–55%. One series has 
reported recurrence rates of up to 90% after surgical resection 
NH2
COOH
Juxtamembrane domain     Exon 11 mutations – 65
ATP/imatinib binding domain
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Figure 1 KIT receptor and location and frequency of mutations.
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(Ng et al 1992). Most recurrences occurred within the ﬁ rst 
2 years of resection. Prognostic factors for recurrence are 
shown in Table 2.
There is no standard follow up regimen for resected GIST. 
As recurrent disease can be treated by surgery or imatinib, 
active follow up is warranted. Suggested follow up protocols 
have been developed according to risk groups. For example, a 
high risk patient should have a CT scan every 3–4 months for 3 
years, then every 6 months to 5 years. For low risk, a CT scan 
every 6 months for 5 years is acceptable (Blay et al 2005).
The commonest sites of metastases are the liver and
intraperitoneum. There is some evidence that metastatectomy 
can improve survival in selected patients (Chen et al 1998). 
Those that beneﬁ t most have a disease free interval of greater 
than 12 months, well differentiated histology and an isolated 
liver metastasis. Surgery can be used for palliation, but with 
the advent of imatinib, it has largely been superseded.
Chemotherapy
Interpretation of results from previous studies is difﬁ cult as it 
is likely that many tumors classiﬁ ed as leiomyosarcomas were 
actually GIST. Given this reservation, the efﬁ cacy of chemo-
therapy is low, with response rates less than 10% (Dematteo 
et al 2002). Doxorubicin and ifosfamide have limited activity 
in GIST compared to other soft tissue sarcomas. One study of 
26 patients with GIST showed 38.4% to express P-glycoprotein 
and 35.4% expressed MRP1 (multi drug resistance protein). 
These levels were signiﬁ cantly higher than for soft tissue 
leiomyosarcoma. This may explain the poor response of GIST 
to standard chemotherapy (Plaat et al 2000).
Radiotherapy
Radiation therapy has little role to play in the management of 
GIST. Most tumors are not amenable to treatment because of 
their location and close proximity to vital organs. GISTs are 
thought to be relatively radio-resistant. Nevertheless, radio-
therapy can be successfully used in patients with advanced 
disease to control bleeding or other troublesome symptoms.
Hepatic artery embolization
This technique may provide palliation in patients with GIST 
metastatic to the liver. Due to the vascular nature of GIST, 
occluding the supplying artery may be effective. There has 
been more interest in chemoembolization, which allows 
increased local drug delivery, but reduced systemic effects 
due to high ﬁ rst pass metabolism in the liver. Two small 
studies have shown limited efﬁ cacy with responses lasting 
8–12 months (Mavligit et al 1995; Rajan et al 2001).
Development of imatinib mesylate
Imatinib was developed as a tyrosine kinase receptor inhibi-
tor. In 1989, a family of compounds called tyrphostins were 
shown to have speciﬁ city for the epidermal growth factor 
receptor. Further developments led to the identiﬁ cation of 
2-phenylaminopyrimidine compounds as having the most 
promising inhibitory activity against receptor tyrosine 
kinases. This led to the development of imatinib, which was 
shown to inhibit the intracellular kinases ABL and BCR-
ABL fusion protein in chronic myeloid leukemia (CML) 
cells (Druker et al 1996), but was subsequently found to 
have comparable activity against the KIT receptor (wild 
type and mutant) and PDGFR (Carroll et al 1997; Heinrich 
et al 2000).
Imatinib is a competitive antagonist of the adenosine 
triphosphate (ATP) binding site. It blocks the transfer of 
phosphate groups from ATP to tyrosine residues of the sub-
strates. This causes interruption of the downstream signalling 
process that leads to cell proliferation, including MAP kinase 
and Akt (Heinrich et al 2000).
Pharmacology of imatinib mesylate
Pharmacokinetic studies of imatinib in healthy volunteers, 
patients with CML and GIST have shown good oral absorp-
tion and a bioavailability of 98%, regardless of the prepara-
tion (solution, capsule or tablet) or dosage strength (100 mg, 
400 mg) (Peng et al 2005). Once absorbed, it binds to serum 
proteins (mainly albumin and alpha 1-acid glycoprotein) and 
peak concentrations are reached 4 hours after administration 
(D’Amato et al 2005).
The main circulating metabolite is an N-demethylated 
piperazine derivative which accounts for 16% of the AUC 
(area under the curve) for imatinib. This, with imatinib 
accounts for most of the activity, but there are a number 
of smaller metabolites. CYP3A4 is the major cytochrome 
P450 involved in imatinib metabolism. Thus, drugs that are 
co-administered may alter the pharmacokinetics. Erythro-
mycin, ﬂ uconazole, and rifampicin have shown inhibition 
of imatinib metabolism. Imatinib increases exposure to 
simvastatin. Alprazolam, caffeine, clindamycin, clonazepam, 
cortisol, ethinyl oestradiol, and verapamil may cause toxic 
Table 2 Prognostic factors for recurrence
Tumor size 5 cm
High grade
Tumor rupture
Small bowel origin
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effects when given with imatinib. St. John’s wort increases 
imatinib clearance by 43%. Patients should avoid excessive 
amounts of paracetamol as both are metabolized by CYP3A4 
(D’Amato et al 2005; Novartis 2005).
The terminal elimination half-life is approximately 18 
hours, which allows for once a day dosage. Excretion is 
via the feces and urine, the majority being the metabolites. 
In patients with GIST, steady state exposure was 1.5 fold 
higher than that observed in CML for the same 400 mg/day 
doseage. This mainly seems to depend on albumin, white 
blood count and bilirubin. Hepatic and renal dysfunction and 
liver metastases may cause variable and reduced metabolism 
of the drug. Age, race, sex, and bodyweight do not signiﬁ -
cantly affect the pharmacokinetics of the drug (Peng et al 
2005; Novartis 2005).
Preclinical studies of imatinib
Druker and colleagues ﬁ rst recognized the BCR-ABL protein 
to be an excellent target for imatinib as the BCR-ABL muta-
tion is present in the vast majority of patients with CML. 
They showed that imatinib inhibited proliferating myeloid 
cell lines speciﬁ cally. 95% reductions in concentrations of 
the abnormal protein were seen. Little toxicity was seen in 
normal bone marrow cells. Very rapidly in vitro results were 
tested in vivo, with signiﬁ cant effects of imatinib seen in nude 
mice and then humans with chronic phase CML (Savage and 
Antman 2002; Druker et al 1996).
The early success of imatinib in chronic phase CML led 
investigators to assess its effects on c-KIT receptor tyrosine 
kinase activity (Heinrich et al 2000). C-KIT autophosphory-
lation, activation of mitogen activated protein (MAP) kinase 
and activation of Akt were all inhibited in a c-KIT expressing 
cell line. In a cell line with an activating mutation of c-KIT, 
more potent inhibitory effects occurred as compared to the 
wild-type receptor. These ﬁ ndings led to the use of imatinib 
in the ﬁ rst patient in 2001 as discussed below (Joensuu et al 
2001).
Phase I studies
Following on from the preclinical studies, imatinib was tested 
in a phase I study in patients with Philadelphia chromosome 
positive CML (Druker et al 2001). This and subsequent 
studies established that a continuous dosing schedule of 
400 mg/day was safe and effective in CML. The ﬁ rst GIST 
patient to receive imatinib was a 50-year-old woman, with 
KIT-positive metastatic GIST associated with a mutation 
in exon 11. She had progressive metastatic disease despite 
surgery, combination cytotoxic chemotherapy, thalidomide 
and interferon alpha. She was treated with 400 mg of imatinib 
per day and response was evaluated using 18-FDG PET (18-
ﬂ uorodeoxyglucose positron emission tomography) and CT 
scanning. After 1 month, the patient had a complete metabolic 
response and by 8 months many of the liver metastases had 
disappeared or reduced in size (Joensuu et al 2001).
A formal phase I study was conducted by the EORTC 
(European Organisation for Research and Treatment of Can-
cer) Soft Tissue and Bone Sarcoma Group (van Oosterom 
et al 2001). 40 patients (36 with GIST and 4 with non-GIST 
soft tissue sarcoma) were recruited between August and 
December 2000. The dose groups of imatinib were 400 mg 
once daily, 300 mg twice daily, 400 mg twice daily, and 
500 mg twice daily. Dose limiting toxic effects were nausea, 
vomiting, oedema and skin rash which were seen at a dose 
of 500 mg twice daily. The maximum tolerated dose recom-
mended was 400 mg twice daily. No responses were seen in 
non-GIST sarcomas. Among the GIST patients, responses 
were seen at all dose levels. Fifty-four percent achieved a 
partial response, 37% had stable disease, and 5% had pro-
gressive disease. After 9 months of therapy, 82% of GIST 
patients continued to obtain clinically important beneﬁ ts. 
In the update, the most common adverse effects for those 
continuing on therapy were periorbital oedema (40%) and 
peripheral oedema (37.5%) (van Oosterom et al 2002).
Phase II studies
After the success of the initial studies in GIST and CML, fur-
ther studies were conceived. The ﬁ rst trial was a US – Finland 
trial, which was a multicentre, randomized, open label phase 
II study (Demetri et al 2002). One hundred and forty-seven 
patients with unresectable or metastatic GIST were randomly 
assigned to receive 400 mg or 600 mg of imatinib daily, 
between July 2000 and April 2001. For those who progressed 
on 400 mg daily, the dose was increased to 600 mg daily. 
After a median follow up of 21 months, 66% achieved a 
partial response and 17% had stable disease. No signiﬁ cant 
differences were seen between the two dose groups. 14% 
died of progressive disease. Median survival had not been 
reached, but 85% were estimated to be alive at 19 months. 
The trial was not powered to distinguish between efﬁ cacy at 
the two dose levels. However a third of those who progressed 
on the lower dose sustained a subsequent partial response on 
crossover (Blanke et al 2004).
A phase II trial of the EORTC Soft Tissue and Bone Sar-
coma Group conﬁ rmed these ﬁ ndings (Verweij et al 2003). 
This study was designed to test the efﬁ cacy of imatinib at the 
maximum tolerated dose of 400 mg twice daily. A total of 
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51 patients participated, 27 of whom had conﬁ rmed GIST, 
24 with other soft tissue sarcomas. In the GIST group, 4% 
had complete remission, 67% partial remission, 18% stable 
disease, and 11% progressive disease. In contrast, there were 
no objective responses in the non-GIST sarcoma group. 
Among GIST patients, the median time to onset of response 
was 113 days. 73% of GIST patients were free from disease 
progression at 1 year. In terms of toxicity, the most frequent 
adverse effects were anemia (92%), oedema, particularly 
periorbital (84%), rash (69%), and fatigue (76%). Granulo-
cytopenia was less common at 48%. These studies led to the 
registration of imatinib for the treatment of locally advanced 
or metastatic GIST in 2002.
A Japanese phase II randomized study evaluated 74 
patients with unresectable or metastatic GIST. Patients 
received either 400 mg daily or 600 mg daily. The results 
showed slightly lower response rates of 55% (overall) and a 
partial response rate of 41%. Interestingly, there were more 
responses in the higher dose group (61% vs 47%), but this 
did not reach statistical signiﬁ cance. The higher dose group 
had more interruptions of therapy as well as dose reductions. 
Grade 3 or 4 neutropenia and dermatitis was also signiﬁ cantly 
higher. The investigators therefore recommended 400 mg 
daily as the optimal dosing schedule (Doi et al 2004).
Response assessment
In clinical trials in patients with advanced GIST treated with 
imatinib, the median time to objective response is about 13 
weeks (Demetri et al 2002). However, some patients have a 
dramatic improvement in symptoms and signs within days, 
accompanied by evidence of reduced metabolic activity on 
PET scans. Interestingly, no cases of tumor lysis syndrome 
have yet been described. The changes following an imatinib 
response can be quite distinct. Commonly cystic changes 
develop that could be confused with progressive disease 
(Linton et al 2006; Ryu et al 2006). Therefore traditional 
response assessment criteria are not entirely relevant. In the 
original patient treated with imatinib, biopsy specimens at 
1 and 2 months after starting treatment showed a marked 
decrease in tumor cells as well as myxoid degeneration and 
scarring. No necrosis or inﬂ ammatory reaction was seen. The 
tumor cells did not stain for Ki-67 (a proliferation marker) 
suggesting relatively low activity (Joensuu et al 2001).
Many trials have used CT and 18-FDG PET in the 
assessment of imatinib response. One study compared CT, 
PET and dual modality PET/CT monitoring the effects 
of imatinib therapy in 20 patients. PET/CT identified 
282 metastases, CT picked up 249 lesions and PET alone 
showed 135. In evaluating disease at 3 and 6 months of 
therapy, PET provided 100% accuracy for response, com-
pared to 57%–60% using CT. PET also detected responses 
earlier than CT (Antoch et al 2004). In a similar study of 28 
assessable patients, the absence of FDG uptake after initial 
treatment was associated with a better prognosis than those 
with residual uptake. CT detected more lesions, but was 
less good at predicting prognosis (Goerres et al 2005). A 
further study showed PET response was associated with a 
signiﬁ cantly longer progression free survival (Stroobants 
et al 2003; King 2005).
Choi and colleagues have proposed new response crite-
ria for GISTs. They studied 172 lesions in 40 patients with 
metastatic disease. Patients were assessed pre-treatment and 
after 2 months with CT imaging and FDG-PET. A decrease in 
tumor size of more than 10% or a decrease in tumor density of 
more than 15% on CT had a speciﬁ city of 100% and a sensi-
tivity of 97% in identifying PET responses. This compares to 
100% speciﬁ city and 52% sensitivity using RECIST criteria. 
Thus, RECIST criteria are felt to be a poor indicator of clini-
cal beneﬁ t, underestimating the effects of treatment (Choi 
et al 2007). These new criteria have been further evaluated 
and correlation has been shown with time to tumor progres-
sion and disease speciﬁ c survival. No similar correlation was 
seen using RECIST criteria (Benjamin et al 2007).
Following initial response to imatinib, resistance often 
develops. There have been reports of a characteristic new 
nodule-within-a-mass pattern of recurrence (Shankar et al 
2005). In this series of 92 patients treated with imatinib, 39 
developed progressive disease and 21 of them showed this 
pattern. It was the ﬁ rst sign of progression in the majority with 
this feature. The authors postulate that this pattern represents 
a localized clone of mutant tumor cells developing resistance 
to c-KIT inhibition. This is important, as traditional response 
criteria may not identify the ﬁ rst signs of recurrent disease.
Phase III trials
There have been two large randomized controlled phase III 
trials assessing the optimum dosage of imatinib. The EORTC 
Soft Tissue and Bone Sarcoma Group conducted the largest 
randomized phase III trial (Verweij et al 2004). 946 patients 
with histologically proven advanced or metastatic GIST (c-
KIT positive) were randomized to receive imatinib 400 mg 
or 800 mg daily. The option of crossover to the higher dose 
was offered to patients with progression on 400 mg daily. 
The primary end point was progression free survival. The 
median follow up was 25 months. Response rates were equal 
in both arms: objective response rate (complete and partial 
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response) was 50% for the 400 mg group and 54% in the 
800 mg group. 56% had progression on 400 mg compared 
to 50% on 800 mg (HR 0.82, 95% CI 0.69–0.98, p = 0.026). 
Overall survival was 85% at 1 year and 69% at 2 years for 
the 400 mg group and 86% at 1 year and 74% at 2 years for 
the 800 mg group. There were more dose reductions and 
interruptions in the higher dose group. Toxicity was common 
but manageable. Oedema, anemia, rash, lethargy, nausea, 
bleeding, diarrhoea, and dyspnoea were statistically more 
common in the 800 mg group. Table 3 shows the frequency 
and grade of toxicity for those receiving 400 mg/day.
The North American Sarcoma Intergroup study (S0033) 
randomized 746 patients to either 400 mg or 800 mg daily 
of imatinib. Patients randomized to 400 mg daily were dose 
escalated to 800 mg daily on disease progression. The pri-
mary end point was overall survival. Early results presented 
in abstract in 2003 showed no difference in overall survival 
or progression free survival, after a median follow up of 14 
months. The proportion of patients achieving an objective 
response or stable disease was similar in both arms (75% 
(400 mg) vs 73% (800 mg)). Objective response rates were 
43% vs 41% respectively (Benjamin et al 2003). In the 2004 
update, after a median follow up of 25 months, the median 
survival had not been reached. 2 year survival for the 400 mg 
vs 800 mg group was 73% and 78% respectively, 2 year pro-
gression free survival was 50% and 53% respectively. Again 
these were not statistically different. Eighty-eight patients 
crossed over to the higher dose on disease progression. Of 
these, 7% demonstrated partial response and 29% achieved 
stable disease (Rankin et al 2004).
These two studies have shown differing results. The 
North American study with overall survival as primary end 
point has to date shown no differences between the two dose 
groups. In contrast, the EORTC study, with progression free 
survival as its primary end point, has shown a statistically 
signiﬁ cant improvement in progression free survival, but 
requires further follow up to assess overall survival. In both 
studies, survival results may be inﬂ uenced by the cross over 
design.
At ASCO 2007, the GIST Meta-analysis Group presented 
the results of a meta-analysis of these two randomized stud-
ies. After a median follow up of 45 months, a small but 
signiﬁ cant progression free survival advantage was seen in 
the high dose arm. Overall survival was identical in the two 
arms (median survival 4.08 years (bid) vs 4.05 years (od), 
HR 1.00). Compared to KIT exon 11 mutants, wild type 
KIT, exon 9 and other mutations conferred a poorer prog-
nosis. The interaction between dose effect on progression 
free survival and prognostic factors was signiﬁ cant for KIT 
exon 9 mutations, but not for other factors. The heterogeneity 
between the two trials is still being evaluated (Van Glabbeke 
et al 2007).
The results of an interesting phase III trial have recently 
been reported by the French Sarcoma Group (Blay et al 2007). 
It was a prospective randomized trial comparing continuous 
and interrupted use of imatinib beyond 1 year of treatment in 
patients with advanced GIST. Between May 2002 and April 
2004, 182 patients were enrolled. Of these, only 58 were eli-
gible for randomization after 1 year with controlled disease. 
26 patients continued with imatinib, whilst 32 discontinued 
until progression. Documented progression was seen in 8 
of 26 patients in the continuous group and 26 of 32 patients 
in the interrupted group (p  0.001). However, 24 of the 
latter subsequently responded to reintroduction of imatinib. 
There were no differences in survival, resistance or quality 
of life between the two groups. This study supports the use 
of continuous imatinib, due to the high level of progression 
after interruption of therapy. In a further French study, 35 
patients free from progression after 3 years of imatinib at 
400 mg/day, were randomly offered to continue or interrupt 
treatment. 9 progressors were reported after a median fol-
low up of 5.3 months, all of whom achieved tumor control 
(at least stable disease) after rechallenge with imatinib. This 
study continues (Le Cesne et al 2007).
Neoadjuvant and adjuvant imatinib
The success of imatinib in controlling locally advanced 
and metastatic GIST has led to interest in the neoadju-
vant and adjuvant use of the drug. There have been case 
reports and series suggesting a role for the neoadjuvant 
Table 3 Frequency of side effects (400 mg/day dose)
Symptom Any grade % Grade 3 or 4 %
Anemia 89 7
Oedema 71 2
Fatigue 68 6
Pleuritic pain  51 4
Nausea 49 3
Diarrhoea 48 2
Leucopenia 43 3
Granulocytopenia 41 7
Rash 27 2
Vomiting 26 3
Anorexia 26 2
Myalgia 24 0
Pruritus 16 1
Constipation 16 1
Derived from Verweij et al 2004.
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approach (Bauer et al 2005; Loughrey et al 2005; Raut et al 
2006). In a series of 90 patients reported by Bauer and col-
leagues, 12 were rendered suitable for surgical resection of 
residual disease. Eleven of these patients achieved a com-
plete resection, although most had viable tumor cells in the 
resected specimen. The median overall survival was 46 (range 
4–85) months. This report has therefore shown prolonged 
survival and a signiﬁ cant rate of subsequent resectability 
after treatment with imatinib induction. In another series, 
Raut et al evaluated 69 consecutive patients with advanced 
GIST treated by surgery whilst receiving imatinib or another 
tyrosine kinase inhibitor, sunitinib malate (SU11248; Sutent®, 
Pﬁ zer inc, New York). Surgical outcome correlated strongly 
with pre-surgery disease status. There was no evidence of 
residual disease in 78% with stable disease before surgery, 
in 25% with limited progression and in 7% with generalized 
progression. One-year progression free survival was 80%, 
33%, and 0% for stable disease, limited progression and gen-
eralized progression respectively. One-year overall survival 
was 95%, 86%, and 0% for the same groups. These reports 
suggest a role for primary imatinib therapy and surgery for 
advanced GIST. Selected patients may experience prolonged 
survival after this aggressive initial approach. However, the 
actual beneﬁ t of imatinib followed by surgery still requires 
further evaluation in prospective clinical trials. Such trials 
are underway and are shown in Table 4. Neoadjuvant imatinib 
is not recommended where a change in tumor size will not 
affect surgery (Blay et al 2005). It can, however, be consid-
ered where a tumor response could permit function-sparing 
surgery, eg, rectum or oesophagus.
There has also been signiﬁ cant interest in the use of ima-
tinib in the adjuvant setting. This stems from the successes of 
treatment of advanced disease with the rationale that it may be 
more effective in minimal residual disease and may be curative 
in this setting. In high risk patients, the rates of recurrence after 
primary surgery are about 50%. Prospective trials are running 
to assess the role of imatinib following surgery for high risk 
GIST and are shown in Table 4 (NCI, 2007). The ACOSOG 
Z9001 study randomized 708 patients following complete 
resection of a primary GIST of at least 3 cm diameter, to either 
1 year of imatinib 400 mg/day or placebo. Upon recurrence, 
patients could be crossed over from placebo to imatinib, or 
their imatinib dose increased to 800 mg/daily. The trial was 
stopped early after a planned interim analysis, with a median 
follow up of 1.2 years. The primary endpoint of 1-year relapse 
free survival was 97% in the imatinib arm and 83% in the 
placebo arm, with a hazard ratio of 0.325 (p = 0.0000014). It 
appears the signiﬁ cant beneﬁ t occurs in the ﬁ rst 18 months, 
Table 4 Neoadjuvant and adjuvant trials of imatinib in GIST
Trial Title Phase
RTOG-S0132 A phase II trial of  2
 neoadjuvant/adjuvant STI-571 for 
 primary and recurrent operable 
 malignant GIST expressing the 
 KIT receptor tyrosine (CD117) 
MDACC ID03-0023 A prospective, randomized, phase 2
 II study of preoperative plus 
 postoperative imatinib mesylate 
 (Gleevec®, formerly STI-571) in 
 patients with primary, recurrent, 
 or metastatic resectable, Kit- 
 expressing, gastrointestinal 
 stromal tumor (GIST) 
ACOSOG-Z9000 A phase II study of adjuvant 2
 STI571 (Gleevec®) therapy in 
 patients following completely 
 resected high-risk primary 
 gastrointestinal stromal tumor 
 (GIST). 
ACOSOG-Z9001 A phase III randomized double- 3
 blind study of adjuvant STI571 
 (Gleevec®) versus placebo in 
 patients following the resection 
 of primary gastrointestinal 
 stromal tumor (GIST).
EORTC 62024 Intermediate and high risk 3
 localized, completely resected, 
 gastrointestinal stromal tumors 
 (GIST) expressing KIT receptor: 
 a controlled randomized trial on 
 adjuvant imatinib mesylate 
 (Glivec®) versus no further 
 therapy after complete surgery 
SSGXVIII Short (12 months) versus long 3
 (36 months) duration of adjuvant 
 treatment with the tyrosine kinase 
 inhibitor imatinib mesylate of 
 operable GIST with a high risk 
 for recurrence: 
 a randomized phase III study 
KRDI-TUM-GIST- Open-label trial of neoadjuvant 2
CST1571-BDE43 imatinib mesylate (Glivec®) in 
 patients with locally advanced 
 malignant gastrointestinal stromal 
 tumors (GIST) expressing c-KIT 
 or platelet-derived growth factor 
 receptor-alpha 
AMC-ONCGI-0501 Phase II study of imatinib 2
 mesylate as adjuvant treatment in 
 high-relapse risk localized 
 gastrointestinal stromal tumors 
 with c-KIT mutation
Abbreviations: ACOSOG, American College of Surgeons Oncology Group; AMC, 
Asan Medical Center – University of Ulsan College of Medicine; EORTC, European 
Organization for Research and Treatment of Cancer; KRDI-TUM, Klinikum Rechts 
Der Isar – Technische Universitaet Muenchen; RTOG, Radiation Therapy Oncology 
Group; MDACC M. D.  Anderson Cancer Center; SSG, Scandinavian Sarcoma Group. 
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but then the recurrence rate is similar in both arms. This has 
brought concern that early treatment may lead to the early 
development of resistance. Longer follow up required to see 
if there is an improvement in overall survival, although con-
tamination of the placebo group may jeopardise this analysis 
(DeMatteo et al 2007). The EORTC study (62024) of adjuvant 
imatinib selects patients on the basis of intermediate or high 
risk of recurrence, rather than tumor size alone. Patients are 
randomized to 2 years treatment with imatinib 400 mg/day or 
observation. The primary endpoint is overall survival, and the 
study is expected to complete accrual by January 2008.
Imatinib resistance
Two types of resistance to imatinib treatment exist: primary 
resistance (on initial use of the drug) and secondary resistance 
(after an initial response). Ten to ﬁ fteen percent of patients 
are primarily resistant to treatment with imatinib. Fletcher 
and associates evaluated 3 patients with primary and 13 
patients with secondary resistance (Fletcher et al 2003). Four 
mechanisms of imatinib resistance were identiﬁ ed: 1) Target 
resistance due to mutation – a new KIT or PDGFRα point 
mutation and protein activation, superimposed on the original 
mutation in that gene. 2) KIT genomic ampliﬁ cation with 
overexpression of the KIT oncoprotein, without a new point 
mutation. 3) Target modulation – activation of an alternate 
receptor tyrosine kinase protein, accompanied by loss of 
KIT oncoprotein expression. 4) Functional resistance – KIT 
or PDGFRα activation, outside the juxtamembrane hotspot 
regions, in the absence of a secondary point mutation. All 
these mechanisms were involved in late resistance, but only 
4) was seen in primary resistance. At progression, all GISTs 
showed activation of essential downstream pathways depen-
dent on KIT or PDGFRα oncogenic stimulation in untreated 
tumors. In PDGFRα exon 18 (90% of all PDGFRα), the 
point mutations have been shown to be resistant to imatinib. 
The in-frame deletions are, however, sensitive to imatinib. 
A further study showed secondary mutations in almost half 
of patients with acquired resistance (Antonescu et al 2005). 
These all had a primary exon 11 mutation and mostly exon 17 
secondary mutations. Primary resistant tumors did not con-
tain secondary mutations. Other studies have also shown new 
KIT mutations as a cause for secondary resistance to imatinib 
(Wardelmann et al 2005; Bertucci et al 2006; Wardelmann 
et al 2006). RNA interference has revealed imatinib resistant 
GIST cells are still dependent on KIT kinase activity for 
activation of essential downstream signalling pathways. HSP 
90 inhibition has been shown, in preclinical studies, to be a 
possible solution to imatinib resistance (Bauer et al 2006).
As part of the EORTC phase III study, various co-factors 
were studied to assess if they played a part in early or late 
resistance (Van Glabbeke et al 2005). Initial resistance 
occurred in 12%. This was independently predicted for by 
the presence of lung metastases and the absence of liver 
metastases. Predictors of late resistance were high baseline 
granulocyte count, a non-stomach primary tumor, large 
primary size, and low initial imatinib dose.
There may also be a pharmacological reason behind ima-
tinib resistance (De Giorgi and Verweij 2005). Toxic effects 
of imatinib decrease over time as does the exposure of the 
drug (Judson et al 2005). Dose related effects have been seen 
in some of the clinical studies which may suggest a change 
in the pharmacokinetics during drug exposure could result 
in a change in the efﬁ cacy of the drug.
Other clinical studies
There have been many studies in the imatinib era which have 
been evaluating the effects of imatinib treatment in clinical 
practice. In the pre-imatinib era, surgery was the mainstay 
of treatment. For example, 5-year overall survival in surgical 
series have ranged between 21% and 95%, partly depending 
on the grade of tumor included (Wu et al 2003, Bucher et al 
2006). GISTs of the jejunum and ileum treated surgically 
have been shown to have a 39% tumor related mortality, 
which was twice that of gastric GISTs (Miettinen et al 2006). 
Case series assessing the use of imatinib in advanced disease 
have shown comparable responses to the trial data, with 
overall responses in excess of 80% (Schindler et al 2005; 
Kasper et al 2006,).
The role of surgery is now changing in the face of ima-
tinib prolonging survival of advanced disease. The ESMO 
consensus meeting in 2004, suggested that surgical resection 
of disease after an imatinib response (usually after 4–12 
months) still remains experimental (Blay et al 2005). Global 
progression after imatinib is certainly a contraindication to 
radical surgery (Raut et al 2006). The use of surgery for lim-
ited intra-abdominal metastatic disease and locally advanced 
disease after imatinib is unproven, but appealing. Resection 
of isolated recurrent disease has not been shown to confer a 
signiﬁ cant survival beneﬁ t (Neuhaus et al 2005). However, 
with the use of imatinib, liver metastatectomy may produce 
long term survival, in excess of 24 months (Sakakura et al 
2006). Careful selection may improve results, with data 
suggesting a disease free interval of more than 18 months, 
particularly for peritoneal or liver recurrence (Kosmadakis 
et al 2005). Good clinical responses have been seen with 
the use of imatinib in recurrent and metastatic disease, but 
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the real beneﬁ ts in association with surgery will have to be 
gauged in the light of several ongoing clinical trials (Wu et al 
2003; Benjamin et al 2006).
Future perspectives
The role of imatinib in GIST is now well established. It 
has become a standard of care for advanced and metastatic 
disease. Its role in neoadjuvant and adjuvant therapy is cur-
rently the subject of clinical trials. Evidence for the use of 
mutational analysis is increasing. This could be used to give 
information on tumor aggressiveness and potential response 
to therapy. Debiec-Rychter and colleagues have shown 
the presence of KIT exon 9 activating mutations and the 
absence of detectable KIT or PDGFRα predict for a worse 
outcome. However, expression of exon 9 KIT oncoprotein 
was shown to be associated with an improved progression 
free survival with the higher dose schedule of imatinib. There 
was no difference according to dose in those with the exon 
11 mutation (Debiec-Rychter et al 2006). This suggests that 
those GISTs with an exon 9 mutation should be commenced 
on the higher 800 mg/day dose of imatinib. Others could 
safely be started on 400 mg/day and increased to 800 mg on 
evidence of progression.
Gene expression patterns have been assessed using DNA 
microarray techniques. The gene FLJ10261, encoding for the 
DOG1 protein is speciﬁ cally expressed in GISTs, irrespective 
of KIT or PDGFRA mutation status (West et al 2004). Its 
function is not known, although it seems to be fairly speciﬁ c 
to GIST, rarely being expressed in other soft tissue tumors. 
It may have a future role in diagnosis, especially in PDGFR 
mutants failing to express the KIT antigen.
There are now various newer agents being investigated 
in GIST. Sunitinib, an oral, multitargeted receptor tyrosine 
kinase inhibitor has shown promise in tumor models. Speciﬁ -
cally, it has been shown to inhibit KIT, PDGFR, FMS-like 
tyrosine kinase 3 and VEGF. Its role has now been inves-
tigated in a randomized controlled trial against placebo for 
imatinib resistant GIST patients (Demetri et al 2006). The 
study was unblinded early, as sunitinib gave a signiﬁ cantly 
longer time to tumor progression (27.3 weeks) compared with 
placebo (6.4 weeks). The difference was statistically signiﬁ -
cant (HR 0.33, p  0.0001). However, the trial had a cross-
over design and patients who progressed on the placebo arm 
were offered the active drug. These patients were analysed 
by intention-to-treat as part of the placebo group, which may 
have reduced the observed beneﬁ t of the sunitinib treatment. 
The design of this trial has been questioned (Joensuu 2006). 
There is evidence that the discontinuation of imatinib may 
cause enhanced growth of previously controlled metastases 
and tumor ﬂ are. This may be because patients on imatinib 
have high concentrations of stem cell factor. Thus, for those 
patients discontinuing imatinib, an inferior outcome may 
have occurred than if they continued on imatinib treatment. 
As a result, a larger difference in time to progression was 
seen. The question that needs to be asked now is how does 
sunitinib compare with continued imatinib use in imatinib 
resistant patients?
The most common side effect of sunitinib was fatigue. 
There was no difference in the incidence of grade 3 or 4 
toxicity between the groups, which may reﬂ ect the level 
of disease related symptoms. The rate of hypertension was 
increased in the sunitinib group and this may be due to the 
drugs antiangiogenic properties. There is also a small risk of 
hypothyroidism with long term usuage (Desai et al 2006).
There has been growing interest in the use of VEGF 
inhibitors such as Bevacizumab (a monoclonal antibody 
targeted against the VEGF receptor) in advanced GIST. A 
large phase III trial proposed by SWOG (South Western 
Oncology Group) will be testing its use with or without 
imatinib. A phase II study is currently evaluating the use 
of Sorafenib, a small molecular inhibitor of Raf kinase, 
PDGFR and VEGFR receptor kinase, in patients previously 
progressing on imatinib and sunitinib. PTK787/ZK222584, 
a novel tyrosine kinase inhibitor, is being assessed in another 
phase II trial. Additional multitargeted tyrosine kinase 
inhibitors, including AZD2171 and AMG706 are also being 
investigated. The chemotherapeutic agents docetaxel and 
gemcitabine in combination are to be given in a proposed 
phase II trial. Other new agents are PKC 412 (inhibitor of 
protein kinase C, KIT, PDGFR, and VEGF), BMS-354825 
(tyrosine kinase inhibitor of KIT, PDGFR, abl and src), 
oblimerson sodium (an antisense oligonucleotide inhibiting 
BCL-2), and CCI 779 (a rapamycin analogue inhibitor of the 
protein kinase mammalian target of rapamycin). There are a 
few phase I trials proposed or underway: IPI-504 (an inhibi-
tor of heat shock protein 90) and perifosine and sunitinib in 
combination are two for the future (De Giorgi and Verweij 
2005; NCI 2007).
Other drugs that have been tested in GIST and found 
inactive include ET-743 (trabectedin) and brostallicin.
Conclusion
There has been rapid progress in the management of GIST in 
the 15 years since they were recognized as a distinct tumor 
entity. This has led to changes in the surgical and oncological 
approach to GIST patients. Their management by specialist 
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teams has facilitated multicentre international research, 
leading to the participation of astonishingly high proportions 
of patients in high quality clinical trials. The introduction 
of imatinib mesylate has revolutionized the treatment of 
patients with locally advanced and metastatic GIST, leading 
to important gains in quality of life and survival. The process 
of discovery, development and evaluation of this drug acts 
as a new paradigm for the introduction of other biologically 
targeted agents in cancer.
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